| Gene symbol | NR2E3 | Synonyms | ESCS, PNR, RNR, RP37, rd7 | Type of gene | protein-coding |
| Chromosome | 15 | Map location | 15q23 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | nuclear receptor subfamily 2 group E member 3 | ||||
| GTO ID | GTC3867 |
| Trial ID | NCT06388200 |
| Disease | Retinitis Pigmentosa |
| Altered gene | NR2E3 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | OCU400-301 |
| Phase | Phase3 |
| Recruitment status | Recruiting |
| Title | A Phase 3, Multi-Center, Randomized Study to Assess The Efficacy, Safety and Tolerability of Subretinal OCU400 Gene Therapy for the Treatment of Retinitis Pigmentosa |
| Year | 2024 |
| Country | United States |
| Company sponsor | Ocugen |
| Other ID(s) | OCU400-301 |
| Vector information | |||||||||
|
|||||||||
| Cohort1: RHO mutations arm | |||||||||
|
|||||||||
| Cohort2: Gene agnostic arm | |||||||||
|
|||||||||